ISSN 1662-4009 (online)

ey0017.4-5 | Important for clinical practice | ESPEYB17

4.5. Growth and adult height in girls with Turner syndrome following IGF-I titrated growth hormone treatment

AC Wang , CP Hagen , L Nedaeifard , A Juul , RB Jensen

To read the full abstract: J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa274.This retrospective study evaluated the long-term effects of GH treatment (median duration 6.7 years) in 63 girls with Turner syndrome (TS) whose GH doses were titrated to maintain IGF-I levels within the normal range. The median GH dose to maintain normal IGF-I levels was 33 (g/kg/day. Across all TS karyotypes, IGF-I titrated GH dosing led to a median adult height (AH)...

ey0020.5-6 | Clinical Guidance and Studies | ESPEYB20

5.6. Neuroimaging in 205 consecutive children diagnosed with central precocious puberty in Denmark

AB Hansen , CH Renault , D Wojdemann , P Gideon , A Juul , RB Jensen

Brief summary: This Danish single-center retrospective study evaluated the occurrence of pathological findings on neuroimaging among children diagnosed with central precocious puberty (CPP).CPP incidence has been increasing over the last four decades (1) and is more prevalent in females than in males. Most cases are idiopathic (2) but brain magnetic resonance imaging (MRI) is routinely performed in order to exclude rare pathological causes.<p class="...

ey0021.7-1 | Clinical Guidance and Studies | ESPEYB21

7.1. Girls with idiopathic central precocious puberty did not display substantial changes in body mass index after treatment with gonadotropin-releasing hormone analogues

CS Uldbjerg , YH Lim , CH Renault , D Hansen , A Juul , EV Brauner , RB Jensen

Brief Summary: This retrospective study of 123 Danish girls treated with GnRHa for idiopathic central precocious puberty (CPP) shows that GnRH agonists do not impact body mass index during and after cessation of treatment.The use of GnRH agonists (GnRHa) for treatment of girls with CPP is well established but the potential long term effects of GnRHa remain a matter of debate, especially regarding their impact on weight evolution1,2.<p clas...

ey0020.2-5 | Important for Clinical Practice | ESPEYB20

2.5. Tracking and cumulative lifetime exposure to IGF-I in 6459 healthy individuals and in SGA children treated with GH

ASL Kjaer , RB Jensen , JH Petersen , A Linneberg , LL Karhus , LS Henriksen , TH Johannsen , KM Main , AR Hoffman , A Juul

Brief summary: The objective of this study was to examine whether IGF-I and IGF-binding protein-3 (IGFBP-3) levels track through childhood into adulthood and to estimate the cumulative lifetime exposure to IGF-I in healthy individuals and in individuals with a defined period of increased IGF-I levels because of GH therapy.Measurement of serum IGF-I is a cornerstone in rhGH treatment monitoring. Keeping serum IGF-I concentrations within the normal referen...

ey0021.7-2 | Clinical Guidance and Studies | ESPEYB21

7.2. Differentiation of idiopathic central precocious puberty from premature thelarche using principal component analysis

A Cleemann Wang , CP Hagen , TH Johannsen , AG Madsen , LH Cleemann , P Christiansen , KM Main , A Juul , RB Jensen

Brief Summary: this retrospective study describes clinical and biochemical parameters which, using the principal component analysis, help in the differential diagnosis between idiopathic central precocious puberty (ICPP) and premature thelarche (PT).Breast development in girls before 8 years of age may be related to progressive CPP but can sometimes simply be the consequence of premature thelarche without activation of the hypothalamic-pituitary-gonadal ...

ey0020.2-3 | Important for Clinical Practice | ESPEYB20

2.3. Timing of puberty, pubertal growth, and adult height in short children born small for gestational age treated with growth hormone

EN Upners , LL Raket , JH Petersen , A Thankamony , E Roche , G Shaikh , J Kirk , H Hoey , SA Ivarsson , O Soder , A Juul , RB Jensen

Brief summary: In this study the authors reported the adult height and timing of puberty of a cohort of Danish children born small for gestational age (SGA) and treated with rhGH in comparison with national growth standards. rhGH treatment significantly increased height SDS in adulthood as compared to the height SDS at treatment start. Age at peak height velocity did not differ compared with the reference cohort, although peak height velocity was reduced in SGA subjects. SGA b...